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ABSTRACT Late-onset noninfectious pulmonary complications (LONIPCs) affect 6% of allogeneic
stem cell transplantation (SCT) recipients within 5 years, conferring subsequent 5-year survival of
50%. Lung transplantation is rarely performed in this setting due to concomitant extrapulmonary
morbidity, excessive immunosuppression and concerns about recurring malignancy being considered
contraindications. This study assesses survival in highly selected patients undergoing lung
transplantation for LONIPCs after SCT.
SCT patients undergoing lung transplantation at 20 European centres between 1996 and 2014 were
included. Clinical data pre- and post-lung transplantation were reviewed. Propensity score-matched
controls were generated from the Eurotransplant and Scandiatransplant registries. Kaplan–Meier survival
analysis and Cox proportional hazard regression models evaluating predictors of graft loss were
performed.
Graft survival at 1, 3 and 5 years of 84%, 72% and 67%, respectively, among the 105 SCT patients
proved comparable to controls (p=0.75). Sepsis accounted for 15 out of 37 deaths (41%), with prior
mechanical ventilation (HR 6.9, 95% CI 1.0–46.7; p<0.001) the leading risk factor. No SCT-specific
risk factors were identified. Recurring malignancy occurred in four patients (4%). Lung
transplantation <2 years post-SCT increased all-cause 1-year mortality (HR 7.5, 95% CI 2.3–23.8;
p=0.001).
Lung transplantation outcomes following SCT were comparable to other end-stage diseases. Lung
transplantation should be considered feasible in selected candidates. No SCT-specific factors influencing
outcome were identified within this carefully selected patient cohort.
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Introduction
Allogeneic haematopoietic stem cell transplantation (SCT) represents an established treatment option for
an increasing number of benign and malignant diseases, with procedure rates exceeding 8000 in the USA
and 14500 in Europe annually [1]. Leading indications include acute myeloid leukaemia (AML) and acute
lymphocytic leukaemia (ALL), which currently account for 35% and 16% of procedures, respectively.
Although refinements in SCT protocols have improved early outcomes, late-onset noninfectious
pulmonary complications (LONIPCs) continue to limit long-term survival [2]. LONIPCs occur in 20% of
SCT patients and encompass the entire spectrum of lung disease, ranging from interstitial lung disease,
pleuroparenchymal fibroelastosis to pulmonary veno-occlusive disease and classical bronchiolitis obliterans
[3]. Although the latter has long been considered ubiquitous for pulmonary graft versus host disease
(GvHD), recent studies suggest additional interstitial lung involvement in some patients [4, 5]. Treatment
strategies ranging from oral macrolides to intensified immunosuppression and extracorporeal
photopheresis have demonstrated benefit, but outcomes remain unpredictable and response rates
disappointing [6–8].
Lung transplantation is considered viable treatment in carefully selected patients with various end-stage
lung diseases. Since 1995, over 47000 adult lung transplantation procedures worldwide have been reported
to the International Society for Heart and Lung Transplantation (ISHLT), with emphysema (38%) being
the leading indication [9]. Reports of lung transplantation for LONIPCs extend as far back as 1992 [10],
but data is extremely limited. Of the 450 lung transplantations (1.1%) performed for obliterative
bronchiolitis in the past 20 years, only 65 were attributed to LONIPCs.
Shortages in suitable donor lungs universally limit lung transplant activity, with many regions adopting
weighted scoring systems such as the Lung Allocation Score that focus on disease-related early survival
probability, calculated from existing United Network for Organ Sharing registry data [11]. Inevitably, this
discourages lung transplantation in orphan diseases along with conditions of poorer predicted outcome.
Given SCT volume and the projected incidence of LONIPCs, lung transplantation rates are much lower
than anticipated. Published experience is limited to case series and small cohorts with mixed outcomes,
leading to a common perception that LONIPCs candidates are “high risk” [12–14], with perioperative
sepsis due to excessive prior immunosuppression, complications of previous long-term steroid treatment,
existing microbial colonisation and the ever-present risk of recurring, primary malignancy being cited as
potential pitfalls [14].
The aim of this study is to quantify these risks and evaluate lung transplantation outcomes in carefully
selected SCT patients with LONIPCs in a large multicentre cohort, paying particular attention to
perioperative sepsis and recurring primary malignancy.
Methods
All patients undergoing lung transplantation for LONIPCs following allogeneic SCT at 20 European
centres between 1996 and 2014 were analysed retrospectively. Clinical data pertaining to patient
demographics, SCT treatment protocols, GvHD incidence and subsequent management were collated,
along with imaging and native lung histology data prior to lung transplantation. Subsequent lung
transplantation follow-up data until June 30, 2016 were standardised using detailed reporting protocols.
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Autologous SCT, living-donor lobar lung transplantation following SCT from the same donor and SCT
patients with lung transplantation indications other than LONIPCs, such as smoking-related emphysema,
were excluded. Life-long lung transplantation centre follow-up with a minimum of twice-yearly review was
mandatory.
SCT were considered as being bone marrow transplantations or peripheral blood stem cell transplants
using accepted definitions [15, 16].
Spirometry adhered to American Thoracic Society/European Respiratory Society guidelines and was
performed at each attendance in all centres [17, 18]. Baseline forced expiratory volume in 1 s (FEV1) and
forced vital capacity (FVC) after lung transplantation were individually calculated from the mean of the
two highest values recorded a minimum of 3 weeks apart. Diagnosis of chronic lung allograft dysfunction
(CLAD) required a ⩾3-week reduction in FEV1 of ⩽80% baseline in the absence of an alternative cause.
Subclassification into obstructive bronchiolitis obliterans syndrome (BOS) or restrictive CLAD (rCLAD)
adhered to currently proposed definitions [19–21].
A matched control cohort of non-SCT lung transplantation recipients was generated from the entire
Eurotransplant and Scandiatransplant registries for first lung transplantation between 1996 and 2014 to
compare lung transplantation graft survival. Propensity score matching for sex, age at lung transplantation,
lung transplantation year, lung transplantation procedure (single or bilateral graft) and patient admission
status at lung transplantation was performed using logistic regression with nearest-neighbour matching, a
0.2 calliper and a 1:50 matching ratio. Kaplan–Meier survival curves for overall graft as well as CLAD-free
survival were constructed and the log-rank test used to assess significance.
Factors influencing 1-year mortality and early sepsis were assessed with single and multivariate Cox
proportional hazard regression to calculate hazard ratios with 95% confidence intervals. The proportional
hazards assumption was confirmed, taking p>0.05 upon generation of the respective time-dependent
covariates. Multivariate Cox regression analysis used forward stepwise (likelihood ratio) modelling, taking
p=0.05 and p=0.10 as entry and removal cut-offs at each iteration.
Risk factors for 5-year recurrence of malignancy and 10-year CLAD development were assessed using
competing risk regression, with missing values being omitted over a maximum 10 iterations.
Nonparametric tests were used for all variables and are reported as median (interquartile range (IQR))
unless otherwise stated. Categorical variables were tested with either the Chi-squared test or Fisher’s exact
test. Continuous variables were analysed using the Mann–Whitney U-test or Kruskal–Wallis H-test.
Reported p-values are two-tailed, with p<0.05 being considered significant. Analysis was performed using
SPSS Statistics for Macintosh version 24 (IBM, Armonk, NY, USA) and Prism version 6.0 (GraphPad, La
Jolla, CA, USA).
Results
In total, 112 patients were identified. Seven were excluded from the analysis, with four considered to have
had smoking-related emphysema and three due to autologous rather than allogeneic SCT. Of the 105
patients analysed, 66 (63%) were male. Median (IQR) age at lung transplantation was 31.4 (20.5–
43.5) years, with 18 out of 105 (17%) being <18 years old. AML was the leading SCT indication,
comprising 38 out of 105 (36%) patients. 12 patients had benign diseases, including thalassaemia, severe
combined immunodeficiency, Wiskott–Aldrich syndrome and paroxysmal nocturnal haematuria.
Demographic data are summarised in table 1.
All patients exhibited advanced lung disease with median FEV1 18% and FVC 35% predicted. Our
previously reported clinical dichotomy in LONIPCs persisted [4]. Interstitial fibrosis was found in 51 out
of 105 explanted lungs (49%), corresponding to lower FVC (31% versus 45% predicted; p=0.005) and TLC
(89% versus 110% predicted; p=0.02) despite similar FEV1 (17% versus 18% predicted; p=0.58) in those
patients.
In the absence of specific guidelines for lung transplantation candidate selection for patients post-SCT, 17
out of 20 centres (85%) reported adapting the ISHLT consensus for cystic fibrosis (colonisation, body mass
index) in conjunction with a 2-year cancer-free interval prior to listing [23]. Otherwise no additional
criteria were reported. In the three remaining centres, formal multidisciplinary collaboration with local
haematologists was undertaken to assure quiescent extrapulmonary GvHD. All centres reported
monitoring serum immunoglobulins prior to transplant, with substitution only being offered to those
demonstrating IgG deficiency in the setting of two or more episodes of infection within 6 months.
During both the peri- and post-lung transplantation phases, considerable variation in standard
management across the 20 centres was evident, due in part to variations in local reimbursement policies
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TABLE 1 Summary of stem cell transplantation (SCT) patient demographics, including
treatment up to and including lung transplantation
Demographics
Patients 105
Male 66 (63)
Age at lung transplantation years 31.4 (20.5–43.5)
Patients <18 years 18 (17)
Never-smoker 88 (84)
FEV1 % pred 18 (15–21)
FVC % pred 35 (25–48)
TLC % pred# 103 (74–119)
Restrictive GvHD phenotype 51 (49)
Airway colonisation 39 (37)
Pseudomonas aeruginosa 20 (19)
Aspergillus fumigatus 8 (8)
eGFR (CKD-EPI) mL·min−1·1.73 m−2 93.1 (84.5–119.3)
SCT
Indication
Acute myeloid leukaemia 38 (36)
Acute lymphoblastic leukaemia 16 (15)
Chronic myeloid leukaemia 18 (17)
Chronic lymphocytic leukaemia 2 (2)
Non-Hodgkin lymphoma 6 (6)
Hodgkin lymphoma 6 (6)
Myelodysplastic syndrome 7 (7)
Nonmalignant disease 12 (11)
Type
Bone marrow 51 (49)
Peripheral blood 54 (51)
Age at first SCT years 22.7 (14.4–36.3)
>1 SCT attempt 6 (6)
Timing of SCT after diagnosis months 11.2 (4.5–21.0)
Conditioning treatment
Reduced intensity 16 (18)
Myeloablative 87 (83)
Busulphan 32 (35)
Cyclophosphamide 47 (52)
Fludarabine 20 (22)
Melphalan 17 (19)
Total body irradiation¶ 46 (53)
GvHD
Involvement of any extrapulmonary site 74 (70)
Skin 52 (49)
Gastrointestinal 31 (30)
Ocular 33 (31)
Mucosal 43 (41)
Extrapulmonary sites n 2 (0–3)
Treatment
Cyclosporine 75 (71)
Steroid 68 (65)
Mycophenolate 31 (30)
Methotrexate 18 (17)
GvHD treatments at lung transplantation n 2 (2–3)
Lung transplantation
Bilateral lung transplantation 89 (85)
Timing of lung transplantation after SCT months 69 (36–122)
Lung transplantation <2 years post-SCT 15 (14)
Induction 35 (33)
Inpatient 38 (36)
Intensive care 23 (22)
Mechanical ventilation only 14 (13)
ECMO only 5 (5)
Combined mechanical ventilation and ECMO 4 (4)
Inpatient stay post-lung transplantation days 37 (23–71)
Patient follow-up post-lung transplantation months 34 (9–75)
Data are presented as n, n (%) or median (interquartile range). FEV1: forced expiratory volume in 1 s; FVC:
forced vital capacity; TLC: total lung capacity; GvHD: graft versus host disease; eGFR (CKD-EPI): estimated
glomerular filtration rate (calculated using the Chronic Kidney Disease Epidemiology Collaboration (2012)
formula [22]); ECMO: extracorporeal membrane oxygenation. #: n=91 patients; ¶: n=86 patients.
https://doi.org/10.1183/13993003.01330-2017 4
RARE LUNG DISEASE | M. GREER ET AL.
across the 12 jurisdictions involved. Induction therapy was routinely used in seven out of 20 centres
(35%), accounting for 35 out of 105 SCT patients (33%). All but one centre used the same agent as for
non-SCT patients. The remaining centre replaced their standard antithymocyte globulin with basiliximab
due to physician preference. In total, 21 out of 105 patients (20%) received basiliximab and 14 out of 105
patients (13%) received antithymocyte globulin. Neither receipt of induction therapy nor either of the
specific agents used appeared to influence the risk of sepsis (HR 0.83, 95% CI 0.21–3.29; p=0.79) or early
mortality (HR 0.30, 95% CI 0.04–2.50; p=0.27).
All centres initiated standard triple immunosuppression post-lung transplantation, combining a
calcineurin inhibitor, antimetabolite and steroids. The commonest protocol was tacrolimus, mycophenolate
and prednisolone, which was used in 79 out of 105 patients (75%). Cyclosporine A was used in the
remaining 26 patients, seven of whom also received azathioprine instead of mycophenolate as per standard
local policy. Prednisolone dosage of ⩽10 mg·day−1 at 4 weeks post-lung transplantation was targeted at all
institutions.
Anti-infective prophylaxis again did not deviate between SCT and non-SCT patients at individual centres,
but significant variation between institutional protocols existed. Life-long Pneumocystis jirovecii
prophylaxis along with fungal prophylaxis in the first 4 weeks was advocated by all centres. Life-long
systemic azole prophylaxis was offered to only 28 out of 105 patients (27%). The remaining centres
reported aggressive management of Aspergillus species if detected during surveillance. Reported rates of
life-threatening fungal infections among the SCT group was low, with only a single fatality reported.
Cytomegalovirus prophylaxis again followed local protocols for all patients, varying between 4 weeks to
12 months depending on the donor and recipient constellation.
Total lung transplantation volume at the participating centres during the observation period was 10693,
with current centre volumes ranging from 15 to 120 procedures per year (median 40 per year). Median
(IQR) patient follow-up post-lung transplantation was 34 (9–75) months.
Graft survival
Graft survival at 1, 3 and 5 years post-lung transplantation was 85%, 72% and 67%, respectively. 37
patients (35%) died, with sepsis and CLAD being the leading causes of death.
Within Eurotransplant and Scandiatransplant, 9895 first-time lung transplantations were performed
between 1996 and 2014. Using the defined criteria, 4075 patients were included in the matched control
cohort (supplementary table S1). Given the comparatively young age and high rates of bilateral lung
transplantation in the SCT cohort, it should be noted that cystic fibrosis (CF) and non-CF bronchiectasis
were disproportionately over-represented (32% versus 18% of the registry cohort) and emphysema
correspondingly under-represented (29% versus 41%). Compared with controls, no differences in graft
survival at 1, 3 or 5 years were evident (figure 1).
16 patients (15%) died within 12 months, of whom 14 did not survive to hospital discharge. Sepsis
accounted for 10 of these deaths. In the univariate Cox regression analysis, the only SCT-specific risk
factors to achieve significance were prior calcineurin inhibitor treatment within 6 months of lung
transplantation and a time interval of <2 years between the final SCT and lung transplantation (table 2).
However, only the latter retained significance in the subsequent multivariate analysis (HR 7.5, 95% CI 2.3–
23.8; p=0.001), along with FEV1/FVC ⩾0.7 (HR 5.0, 95% CI 1.4–17.9; p=0.012) and requiring inpatient
care immediately prior to lung transplantation (HR 3.4, 95% CI 1.2–10.0; p=0.03).
Sepsis
In total, 15 out of 37 deaths (41%) during the observation period were attributable to sepsis. Three deaths
occurred in patients with advanced CLAD exhibiting the BOS phenotype. Eight of the 12 remaining
deaths occurred perioperatively, with median (IQR) survival 42 (24–67) days. Other than a single case of
fatal cytomegalovirus infection within 90 days, no details regarding the fatal pathogens in the remaining
cases were available. Only two had reported colonisation prior to lung transplantation (Pseudomonas
aeruginosa and methicillin-sensitive Staphylococcus aureus, respectively).
Univariate Cox regression identified ALL as the sole SCT risk factor for early sepsis (HR 4.6, 95% CI 1.3–
18.7; p=0.02), alongside deteriorating native lung and kidney function and increasing dependency on
medical support immediately prior to transplant (supplementary table S2). In the multivariate analysis,
only the latter retained significance with intensive care unit (ICU) admission prior to lung transplantation
(HR 5.2, 95% CI 1.2–23.4; p=0.03), mechanical ventilation (HR 6.9, 95% CI 1.0–46.7; p<0.001) and dual
bridging (HR 7.8, 95% CI 6.2–98.3; p=0.001) being relevant.
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Malignancy
Malignancy accounted for eight out of 37 deaths (22%), with all occurring among the 93 patients with
malignant SCT indications. However, only half were due to recurrence of the original malignancy. AML
accounted for two cases in whom recurrence occurred within 12 months of lung transplantation, with
death ensuing within 12 months of diagnosis. Both patients had received lung transplantation within
2 years of SCT, well below the median (IQR) interval of 72 (47–135) months in the other 34 AML
patients.
Single recurrences of ALL and non-Hodgkin lymphoma were recorded, with both presenting much later at
3 and 5 years post-lung transplantation, respectively. Competing risks regression analysis for recurrence
within 5 years of lung transplantation suggested both myeloablative induction therapy at SCT and lung
transplantation within 2 years of SCT as being contributory.
The four remaining fatal malignancies were colorectal cancer, melanoma and two cases of
post-transplantation lymphoproliferative disorder unrelated to the primary malignancy. Taking all eight
malignancies together, the only significant risk factor on multivariate Cox regression was lung
transplantation within 24 months of SCT (HR 6.4, 95% CI 1.3–46.0; p=0.03).
Extrapulmonary chronic GvHD
Chronic GvHD involving other organs was reported in 74 out of 105 patients (70%), with skin
involvement exhibiting the highest prevalence (49%) and gastrointestinal disease the lowest (30%)
(table 1). Within the cohort, neither involvement of specific organs (p=0.88) nor cumulative site
involvement (p=0.95) impacted on lung transplantation survival. Notably, inpatient lung
transplantation had lower rates of extrapulmonary GvHD (27% versus 55%; p=0.007), particularly skin
involvement (25% versus 45%; p=0.03). No differences in incidence regarding ICU or bridging
requirements were observed.
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FIGURE 1 Kaplan–Meier curve showing graft survival following first lung transplantation among allogeneic
stem cell transplantation (SCT) patients as well as matched controls from the other main disease groups. CF:
cystic fibrosis; NCFB: non-CF bronchiectasis; LONIPCs: late-onset noninfectious pulmonary complications
after SCT. Comparing SCT versus non-SCT patients, no differences in survival were observed at 1, 3 and
5 years post-lung transplantation.
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CLAD and re-transplantation
CLAD developed in 29 out of 79 patients (37%) surviving beyond the first year, developing at median
(IQR) 29 (15–56) months post-lung transplantation. Both CLAD phenotypes were evident, with 21 out
of 29 (72%) developing BOS and the remaining eight out of 29 (28%) developing rCLAD. No clear
relationship between CLAD onset or phenotype and previous LONIPC phenotype was evident. rCLAD
TABLE 2 Uni- and multivariate Cox regression analyses assessing risk factors for all-cause mortality ⩽12 months after lung
transplantation
Number of
Patients
Proportional
hazard
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Demographics
Male 66 0.71 2.59 (0.90–7.42) 0.08
Never-smoker 89 0.92 0.45 (0.13–1.54) 0.20
Age per 10-year increase 105 0.18 1.08 (0.74–1.55) 0.70
FEV1 per 10% pred loss 105 0.43 1.12 (0.64–1.89) 0.43
FVC per 10% pred loss 105 0.44 5.14 (1.21–21.88) 0.03
FEV1/FVC ⩾0.7 92 0.32 1.45 (0.27–7.90) 0.67 5.04 (1.42–17.90) 0.012
TLC ⩽90% pred 16 0.55 0.40 (0.14–1.15) 0.09
Isolated bronchiolitis obliterans on
computed tomography
54 0.95 0.79 (0.28–2.24) 0.65
Colonised 39 0.67 1.18 (0.29–4.78) 0.81
Pseudomonas aeruginosa 20 0.27 2.43 (0.23–15.43) 0.46
Aspergillus 8 0.61 0.86 (0.09–8.65) 0.89
eGFR <90 mL·min−1 65 0.53 1.45 (0.54–3.96) 0.46
Primary diagnosis
Acute myeloid leukaemia 38 0.59 1.09 (0.91–1.33) 0.41
Acute lymphoblastic leukaemia 16 0.49 1.95 (0.54–6.98) 0.29
Chronic myeloid leukaemia 18 0.57 0.93 (0.77–1.13) 0.73
Chronic lymphocytic leukaemia 2 0.86 1.69 (0.42–6.77) 0.30
Non-Hodgkin lymphoma 6 0.50 1.04 (0.69–1.45) 0.97
Hodgkin lymphoma 6 0.47 1.01 (0.11–9.48) 1.00
Myelodysplastic syndrome 7 1.00 0.83 (0.76–0.91) 0.59
Benign 12 0.99 0.82 (0.74–0.90) 0.21
SCT
BMT 51 0.32 0.38 (0.13–1.09) 0.07
Multiple SCT 6 0.62 0.95 (0.12–7.91) 0.96
Lung transplantation <2 years
post-SCT
15 0.44 3.32 (1.19–9.23) 0.02 7.46 (2.33–23.84) 0.001
Myeloablation 87 0.69 1.46 (0.19–11.11) 0.71
Busulphan 32 0.58 1.07 (0.27–4.26) 0.93
Cyclophosphamide 47 0.40 1.40 (0.35–5.61) 0.63
Total body irradiation 46 0.92 1.75 (0.60–5.14) 0.31
Extrapulmonary GvHD
GvHD skin 52 0.29 1.56 (0.55–4.44) 0.41
GvHD gastrointestinal 31 0.60 1.35 (0.42–4.38) 0.62
GvHD eye 33 0.12 3.46 (0.83–14.51) 0.09
GvHD mucosa 43 0.50 2.23 (0.70–7.04) 0.18
Calcineurin inhibitor <6 months 75 0.33 2.95 (0.99–8.82) 0.05
Mycophenolate <6 months 31 0.90 0.68 (0.23–2.02) 0.48
Systemic steroids <6 months 68 0.57 0.86 (0.15–3.07) 0.62
Peri-lung transplantation treatment
Bilateral lung transplantation 89 0.69 0.54 (0.33–0.89) 0.02
Induction 35 0.36 0.30 (0.04–2.50) 0.27
Inpatient at lung transplantation 38 0.45 4.46 (1.23–16.15) 0.02 3.40 (1.16–10.01) 0.03
ICU 23 0.36 0.78 (0.12–5.27) 0.80
Mechanical ventilation 14 0.23 8.47 (2.36–37.19) <0.001
ECMO 5 0.48 5.08 (0.50–31.81) 0.17
Dual bridging 4 0.44 10.80 (1.60–42.75) 0.02
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; TLC: total lung capacity; eGFR: estimated glomerular filtration rate; SCT:
stem cell transplantation; BMT: bone marrow transplantation; GvHD: graft versus host disease; ICU: intensive care unit; ECMO: extracorporeal
membranous oxygenation.
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occurred earlier (median 13 versus 47 months; p=0.002) and resulted in earlier graft loss (median 30
versus 71 months post-lung transplantation; p=0.01). Limitations of the registry data used for the
matched control cohort unfortunately prevented accurate comparisons for CLAD-free and with-CLAD
survival. Broad comparisons with ISHLT data for CLAD-free survival, dependent upon surviving
⩾14 days post-lung transplantation, appear favourable (median 5.6 versus 11.9 years), but interpretation
is limited.
Competing risks regression analysis for 10-year CLAD risk identified only need for ICU (p=0.02) and
mechanical ventilation (p=0.01), with no evidence of any immunological associations between CLAD
phenotype and previous GvHD characteristics.
Five redo lung transplantations were performed. Two were attempted for primary graft dysfunction, with
both patients dying within 1 week. CLAD accounted for the remaining procedures, of which two had
rCLAD. One rCLAD patient died perioperatively due to bleeding. The remaining two redo lung
transplantation patients remained alive at study completion, 12 and 20 months post-redo transplant,
respectively.
Discussion
This pan-European experience of lung transplantation in carefully selected candidates with life-limiting
LONIPCs following allogeneic SCT represents the largest known cohort of such patients. The most
significant finding was that survival at 1, 3 and 5 years in this cohort was similar to matched controls with
other end-stage lung diseases.
Given the current reported SCT volumes and reported incidence and outcomes of LONIPCs,
approximately 350 patients die annually in Europe alone. Demonstrating the feasibility of lung
transplantation and generating awareness is important for both pulmonologists and haematologists alike.
Although it is unlikely that all would be suitable lung transplantation candidates, the disparity to current
lung transplantation rates remains hard to ignore.
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FIGURE 2 Kaplan–Meier curve showing graft survival following first lung transplantation among allogeneic
stem cell transplantation (SCT) patients, dependent upon the time interval between procedures (<24 or
⩾24 months). Early survival was worse in those proceeding to lung transplantation within 2 years of SCT, but
beyond the first year no differences remained.
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These findings provide encouraging guidance to lung transplantation physicians, assisting in difficult
decision making regarding candidacy of such patients. Discouragement of orphan diseases is an inherent
limitation of organ allocation systems. With the intent of optimising graft utility, their reliance on 1-year
outcome data tends to discriminate when a critical mass of data does not exist. Furthermore, the body of
evidence available appears to suggest that such carefully selected patients can be managed in a very similar
fashion to other lung transplantation recipients, without affecting outcomes.
Being a retrospective analysis involving numerous centres of varying lung transplantation experience, it is
inevitable given the condition’s reputation that cautious decision making resulted in candidate selection
bias at listing. Young recipient age, high outpatient lung transplantation rates and lack of comorbidities
among hospitalised patients are all suggestive. Ideally, consideration of rejected candidate referrals and
wait-list deaths would add value to the analysis, but obtaining data from all centres proved unfeasible.
While minimising interobserver variability, use of standardised data collection enforced a “lowest common
denominator” approach to maximise completeness, generating more qualitative data. For certain aspects,
such as treatment exposure or extent of disease, greater reliance on quantitative data may have proved
more insightful.
Due caution is encouraged in interpreting the Cox proportional hazard models given the infrequent
events within a small cohort. The spread in the 95% confidence intervals reflect this, casting a degree of
uncertainty that can only be resolved with increasing case volume. As such, the results reflect current
experience to assist physicians facing difficult decision making when assessing or managing such
patients.
Nonetheless, the findings provide an important insight into the factors impacting upon early survival, and
dispel some of the common concerns about sepsis risk and recurring malignancy. The relevance of 1-year
all-cause mortality is rooted in allocation policies. Apart from lung transplantation within 2 years of SCT,
all the identifiable risk factors in the uni- and multivariate analyses reflected the general clinical condition
and, as highlighted in the ISHLT Registry, are by no means exclusive to LONIPCs [9]. Interestingly, the
recent recognition of LONIPC phenotypes appears relevant, as those with restrictive spirometry (FEV1/
FVC ⩾70%: HR 5.0, 95% CI 1.4–17.9; p=0.012) exhibited poorer early survival on multivariate analysis.
However, it is unclear if this reflects patient condition or the duration of prior immunosuppression which,
as stated previously [4], was significantly longer among patients with restrictive lung function (median
(IQR) 54 (30–108) versus 114 (70–152) months; p=0.002).
Early fatal sepsis accounted for eight out of 17 deaths (47%), which appears to exceed (192 out of 781
deaths (25%)) ISHLT Registry reports [9]. Except for ALL, no other SCT-specific factors were identified.
Caution due to the small numbers involved is again advised, but four out of 16 lung transplantation
recipients with a history of ALL died of early sepsis, accounting for half of such deaths. No clear
explanation was evident, but it is noteworthy that sepsis-related death is problematic among ALL patients
following SCT, with immunoglobulin deficiencies being implicated [24, 25]. Importantly, however,
concerns related to prior immunosuppression or microbial airway colonisation could not be substantiated.
The consensus view among the authors was that colonisation should not represent an absolute
contraindication, rather remain an individual case consideration. It should be noted, however, that none of
the cohort were colonised with more contentious pathogens such as Mycobacterium abscessus,
Scedosporium or Burkholderia species.
Recurrence rates of primary malignancy were low at 4%. Given the small numbers involved and
proportionately large number of early deaths of alternative cause, concealed confounders are likely. A
competing risks regression was used to compensate for this, identifying lung transplantation within 2 years
of last SCT as the only risk factor. While AML data appear to support this, the interaction between factors
remains unclear and should be considered in context. Current candidate selection guidelines recommend a
malignancy-free interval of 2 years for all lung transplantation [23] and given the all-cause mortality data
presented here (figure 2), no clear evidence to the contrary can be provided.
Extrapulmonary chronic GvHD causes considerable comorbidity and its lack of influence on outcomes
suggests inadequacy of data. Concerns regarding inadequate nutrition or oral immunosuppression in
gastrointestinal GvHD should be considered analogous to those in CF where attainment of stable body
mass with or without enteral feeding represents a basic lung transplantation requirement [23].
Given their similarities, both in terms of end-organ damage and unpredictable responses to broadly
similar treatment strategies, the development of host versus graft CLAD in patients with existing GvHD
disease is somewhat unique. Unfortunately, no associations regarding incidence, timing or phenotypic
recurrence were found. Furthermore, there was nothing in the observed CLAD demographics to suggest
substantial deviation from reported patterns in other disease groups.
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In conclusion, lung transplantation is a feasible treatment option for refractory LONIPCs in thoroughly
evaluated, carefully selected candidates, with survival rates comparable to other indications. Accurate
characterisation of LONIPCs and timely referral appear important in minimising risk. Candidate
evaluation, selection and perioperative care should adhere to similar local protocols and values afforded to
other end-stage lung diseases.
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